Brief Report Open Access
Outcomes of cardiac myosin inhibitors in hypertrophic cardiomyopathy: an updated brief meta-analysis
Joud Fahed1,*, Asad Ur Rab2, Mohammad Hamza3, Rehman Afraz4, Ali Awad5, Abdul Monem Al Riahi6, Prakash Upreti7
- 1Department of Medicine, Ascension Saint Agnes Hospital, Baltimore, Maryland, USA
- 2Department of Medicine, Foundation University Medical College, Islamabad 44000, Pakistan
- 3Department of Hospital Medicine, Guthrie Cortland Regional Medical Center, Cortland, NY, USA
- 4Department of Medicine, HCA Los Robles Medical Center, CA, USA
- 5Department of Medicine, Detroit Medical Center/Wayne State University, Detroit, Michigan, USA
- 6William Carey University College of Osteopathic Medicine, Hattiesburg, MS, USA
- 7Department of Medicine, Sands Constellation Heart Institute, Rochester Regional Health, Rochester, New York, USA
Corresponding Author
Joud Fahed, joudf1997@gmail.com
Received Date: February 25, 2026
Accepted Date: May 19, 2026
Fahed J, Rab AU, Hamza M, Afraz R, Awad A, Al Riahi AM, Upreti P. Outcomes of cardiac myosin inhibitors in hypertrophic cardiomyopathy: an updated brief meta-analysis. Int J Cardiol Cardiovasc Dis. 2026;6(1):41-44.
Copyright: © 2026 Fahed J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Pathogenic contribute of unaffected cardiac cells in female Fabry cardiomyopathy
Cardiac hypertrophy is one of the most common manifestations of Fabry disease (FD) [1] and it can be the only clinical expression, in the so called cardiac variant, as result of specific mutation of
alpha-galactosidase-A gene (GLA), as the N215S one [2].
Insights into placental cell senescence in pregnancy, preeclampsia, and peripartum cardiomyopathy
Cardiovascular disease (CVD) is a leading cause of maternal mortality worldwide. The molecular mechanisms underlying de novo CVD in pregnancy are not fully understood, which has limited targeted therapeutic development.
Coronary artery fistulae in patients with hypertrophic cardiomyopathy
Myocardial ischemia with multifactorial pathogenesis is frequently noted in hypertrophic cardiomyopathy (HCM). Coronary artery fistulas (CAF) may be found in HCM but their contribution to myocardial ischemia has not been studied. From 1984 to 2022, 43 patients with HCM and CAF (age 6–82 years, mean 58; 58% male; 77% apical variant; 12% obstructive) were reported in medical literature. Single and multiple CAF were reported in 24 (56%) and 19 (44%), respectively. Overall, a total of 70 major epicardial coronary arteries were affected.
Spectrum of congenital coronary artery anomalies in hypertrophic cardiomyopathy: a systematic review
Myocardial ischemia is a frequent finding in hypertrophic cardiomyopathy (HCM) potentially resulting from microvascular dysfunction, extravascular compression, reduced coronary flow reserve, hemodynamic abnormalities, or concomitant atherosclerotic coronary artery disease (CAD). From June 1991 to October 2024, 40 congenital coronary artery anomalies (CCAA) were reported in 30 adults with HCM [age 18–87 (47.6 ± 19.7); 60% male; 37% obstructive; 20% apical variant].
Outcomes of cardiac myosin inhibitors in hypertrophic cardiomyopathy: an updated brief meta-analysis
Obstructive hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disease occurring in approximately 1 in 500 adults worldwide, characterized by left ventricular outflow tract (LVOT) obstruction, symptoms of heart failure, and increased risk of sudden cardiac death.